Stay updated with breaking news from High Acuity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amedisys (NASDAQ:AMED – Get Rating) issued an update on its FY 2023 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $4.14-$4.36 for the period, compared to the consensus estimate of $4.25. The company issued revenue guidance of $2.25 billion-$2.27 billion, compared to the consensus revenue estimate of $2.26 billion. […]
Amedisys (NASDAQ:AMED – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided earnings per share guidance of $4.14-4.36 for the period, compared to the consensus earnings per share estimate of $4.27. The company issued revenue guidance of $2.254-2.274 billion, compared to the consensus revenue estimate of $2.26 billion. Amedisys also updated its […]
Amedisys (NASDAQ:AMED – Get Rating) had its price objective lowered by Barclays from $93.00 to $88.00 in a research report report published on Friday morning, The Fly reports. Several other equities research analysts have also recently issued reports on the company. SVB Leerink cut their target price on Amedisys from $96.00 to $85.00 and set […]
Amedisys (NASDAQ:AMED – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of $4.14-4.36 for the period, compared to the consensus EPS estimate of $4.27. The company issued revenue guidance of $2.254-2.274 billion, compared to the consensus revenue estimate of $2.26 billion. Amedisys also updated its FY 2023 guidance to […]
Amedisys (NASDAQ:AMED – Get Rating) had its price target decreased by Truist Financial from $115.00 to $97.00 in a research note issued to investors on Thursday, The Fly reports. A number of other equities research analysts have also weighed in on AMED. Credit Suisse Group reaffirmed an outperform rating and set a $115.00 price target […]